bullish

ENSC: Game-changing Pain Reliever Begins Phase 3

299 Views17 Jul 2025 00:00
Issuer-paid
Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the...
What is covered in the Full Insight:
  • Introduction to Ensysce Biosciences
  • PF614 Phase 3 Trial Initiation
  • Significance of PF614 and PF614-MPAR
  • Financial and Institutional Support
  • Implications of Clinical Trial Data
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x